[Action of benzbromarone on the renal excretion of allantoin in normouricemic and hyperuricemic humans (author's transl)].
Oral administration of benzbromarone at daily doses of 100 mg or 300 mg over a period of 3 or 6 days does not produce a significant change of the excretion rates of allantoin in the 24-h-urines of humans in a normouricemic or hyperuricemic state. Threrefore, the theroretically improbable assumption that benzbromarone may induce an increased elimination of uric acid by an enteral pathway cannot be accepted any longer. Failing additional direct effects upon purine metabolic pathways (Sorensen and Levinson, 1976) benzbromarone exerts its hypouricemic action solely by uricosuric properties.
D000328:Adult; D000481:Allantoin / Q000652:urine*; D001553:Benzbromarone / Q000008:administration & dosage / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents / Q000008:administration & dosage
D001572:Benzofurans; D014528:Uricosuric Agents; D014527:Uric Acid; D000481:Allantoin; D001553:Benzbromarone
Renale Ausscheidung von Allantoin bei normourikämischen und hyperurikämischen Personen unter der Wirkung von Benzbromaron.